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We detected human metapneumovirus (HMPV) in 54 (5%) of 
1055 children aged 5 to 13 years with acute respiratory illness 
(ARI) identified by outpatient and emergency department sur-
veillance between November and May 2003–2009. Its clinical 
features were similar to those of HMPV-negative ARI, except 
a diagnosis of pneumonia was more likely (13% vs 4%, respec-
tively; P  =  .005) and a diagnosis of pharyngitis (7% vs 24%, 
respectively; P = .005) was less likely in patients with HMPV- 
positive ARI than those with HMPV-negative ARI.
Keywords. acute respiratory illness; human metapneumo-
virus; older children.
 
Human metapneumovirus (HMPV) is associated with acute 
respiratory illness (ARI) in both children and adults [1–7]. The 
spectrum of disease among children can range from mild upper 
respiratory tract infection to lower respiratory tract involve-
ment that presents as bronchiolitis, croup, or pneumonia [1, 2]. 
Many studies that have described the characteristics of HMPV 
infection in children were focused on infants and young chil-
dren, whereas the burden and clinical features of HMPV infec-
tion among older children remain less well defined.
Using prospective population-based surveillance data 
from the Centers for Disease Control and Prevention (CDC)-
supported New Vaccine Surveillance Network (NVSN), our 
group previously described the clinical features associated with 
HMPV infection in young children in inpatient and outpatient 
settings [1]. Here, we analyze data from older children (aged 
5–13 years) who presented to an outpatient facility (outpatient 
clinic or emergency department [ED]) for medical attention to 
define the clinical features and etiologic role of HMPV in this 
age group.
METHODS
Study Design
Surveillance was conducted in the counties surrounding 
Cincinnati, Ohio, Nashville, Tennessee, and Rochester, New 
York, between November and May in 2003–2009. Children 
aged 5 to 13 years who had an ARI were enrolled from the 
outpatient department (OPD) 1 or 2 days/week; patients who 
presented to the ED were enrolled 1 to 4 days/week. ARI was 
defined as an illness that presented with fever and/or 1 or more 
of the following symptoms: cough, earache, nasal congestion, 
rhinorrhea, sore throat, vomiting after coughing, wheezing, 
and/or labored, rapid, or shallow breathing. Children were 
excluded if their symptoms were present for >14 days, if they 
had chemotherapy-associated neutropenia, or if they had been 
hospitalized within the previous 4 days. Additional details of the 
NVSN study design have been reported [1, 8]. After informed 
consent was provided by the parent/guardian, caretakers were 
interviewed to obtain demographic and clinical informa-
tion, including underlying medical conditions, presence and 
duration of symptoms and signs of ARI, and complications 
of illness. Medical records were also reviewed for clinical and 
laboratory information. Information on conditions considered 
to confer higher risk for respiratory illnesses, including prema-
ture birth (<36 weeks’ gestation), chronic pulmonary disease 
(including asthma), cardiac, renal, or immunodeficiency dis-
ease, cancer, or sickle cell anemia, was also obtained. Nasal and 
throat swabs were also obtained from each child for virologic 
testing [8]. After the enrollment visit, the medical records for 
each encounter were reviewed and recorded; the information 
we captured included International Classification of Diseases, 
Ninth Revision (ICD-9) discharge diagnosis codes assigned by 
the respective medical center’s professional coders.
Laboratory Testing
Nasal and throat swabs were combined into a tube of trans-
port medium and delivered at ambient temperature within 1 
to 2 hours to the research virology laboratory at each site. For 
HMPV testing by reverse-transcription polymerase chain reac-
tion (RT-PCR), sample aliquots were collected in lysis buffer 
and frozen at −70°C until shipped in batches to Vanderbilt 
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University for RNA extraction and real-time RT-PCR [1]. The 
RT-PCR assay was designed using a dual-labeled fluorescent 
probe targeting the nucleoprotein (N) gene and was capable 
of detecting <50 RNA copies per reaction. Samples were also 
tested for the presence of respiratory syncytial virus (RSV) and 
influenza. Details of the laboratory methods were described 
previously [9].
Statistical Analysis
Demographic and clinical characteristics of HMPV-positive 
and HMPV-negative ARI in children aged 5 to 13 years were 
compared using Wilcoxon rank-sum and Pearson χ2 tests as 
appropriate for continuous and categorical variables, respec-
tively. We do not present population-based incidence rates 
because the OPD and, to a lesser extent, ED surveillance was 
not completely population based, as are inpatient admissions 
in the NVSN surveillance, although they were representative of 
the study population [1, 10, 11].
RESULTS
A total of 1055 children aged 5 to 13 years with ARI were enrolled 
and provided respiratory samples; 54 (5.1%) of them tested 
positive for HMPV (Table 1). In 48 (88.9%) of these 54 cases, 
HMPV was the only virus detected, whereas RSV was detected 
with HMPV in 4 (7.4%) of the 54, and influenza was codetected 
in 2 (3.7%) of the 54. The median age of these older ambula-
tory children with HMPV infection was 7 years (interquartile 
Table 1. Clinical Features of HMPV Infection in Children Aged 5–13 Yearsa
Feature HMPV-Positive Group (n = 54) HMPV-Negative Group (n = 1001) Total (n = 1055) Pb
Demographics and background characteristics
 Age (median [IQR]) (mo) 84.0 (72.8–114.8) 92.0 (73.0–117.0) 92.0 (73.0–118.0) .435
 Sex (n [%]) .725
  Female 25 (46) 488 (49) 513 (49)
  Male 29 (54) 513 (51) 542 (51)
 Race (n [%]) .399
  Black 22 (41) 542 (54) 564 (53)
  White 13 (24) 202 (20) 215 (20)
  Hispanic 13 (24) 168 (17) 181 (17)
  Other 6 (11) 88 (9) 94 (9)
  Unknown 0 (0) 1 (0) 1 (0)
 High-risk preexisting conditionc 26 (48) 447 (45) 473 (45) .615
 Child born >1 mo early (N = 68) (n [%]) 1 (25) 14 (23) 15 (23) .964
Clinical features of illness (n [%])
 Cough 53 (98) 848 (85) 901 (85) .006
 Shortness of breath 27 (50) 407 (41) 434 (41) .339
 Earache 12 (22) 261 (25) 273 (26) .589
 Sore throat 34 (63) 670 (67) 704 (67) .759
 Fever 35 (65) 713 (71) 748 (71) .511
 Vomiting after cough 20 (37) 260 (26) 280 (27) .196
 Nasal congestion/rhinorrhea 44 (81) 778 (78) 822 (78) .517
 Wheezing 27 (50) 364 (36) 391 (37) .113
 Poor appetite 29 (54) 590 (59) 619 (59) .609
Discharge diagnosis (n [%])
  Asthma 13 (24) 198 (20) 211 (20) .442
  Croup 0 (0) 7 (1) 7 (1) .538
  Fever 3 (6) 78 (8) 81 (8) .548
  Influenza 1 (2) 23 (2) 24 (2) .831
  Otitis media 10 (19) 112 (11) 122 (12) .101
  Pharyngitis 4 (7) 240 (24) 244 (23) .005
  Pneumonia 7 (13) 45 (4) 52 (5) .005
  Sinusitis 2 (4) 23 (2) 25 (2) .508
  Upper respiratory infection 18 (33) 279 (28) 297 (28) .385
  Viral illness 1 (2) 44 (4) 45 (4) .368
  Other acute respiratory illness 7 (13) 38 (4) 45 (4) .001
  Bronchiolitis 2 (4) 8 (1) 10 (1) .032
Bold type indicates a statistically significant result, with statistical significance considered for P < .05. Abbreviations: HMPV, human metapneumovirus; IQR, interquartile range.
aN = 1055, except as specified.
bBold type indicates a significant result.
cHigh-risk preexisting conditions for more severe respiratory illness include premature birth (<36 weeks’ gestation), chronic pulmonary disease including asthma, cardiac, renal, or immunodeficiency disease, cancer, and sickle cell 
anemia.
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range, 6–9 years), and similar proportions of boys and girls were 
affected. In the 54 HMPV-positive children, cough, rhinorrhea, 
fever, and sore throat were the most common features (pres-
ent in 98%, 81%, 65%, and 63% of these children, respectively). 
Wheezing, shortness of breath, and decreased appetite were 
also present in approximately half of the children with HMPV 
infection. Earache and posttussive emesis were uncommon.
Of the 54 children with HMPV infection, 22 (41%) pre-
sented to an ED, and 32 (59%) presented to an OPD. Ages and 
comorbidities present were similar among the children who 
presented to an ED and those who presented to an OPD, and 
the proportions of children with HMPV among those enrolled 
in an ED (22 [4.7%] of 464) and those enrolled in an OPD (32 
[5.4%] of 591) were similar (P = .622). However, children with 
HMPV who presented to an ED were significantly more likely 
to have shortness of breath (17 [77%] of 22) or wheezing (16 
[73%] of 22)  as a presenting complaint than those who pre-
sented to an OPD (shortness of breath, 10 [31%] of 32, P < .001; 
wheezing, 11 [34%] of 32, P  =  .006]. Among all 464 patients 
who presented to an ED, those with HMPV infection were more 
likely to present with wheezing (16 [73%] of 22) or dyspnea (17 
[77%] of 22) than those who tested HMPV negative (wheezing, 
192 [43%] of 442, P = .01; dyspnea, 214 [48%] of 442, P < .01). 
In addition, children who presented to an ED were significantly 
more likely to have a discharge diagnosis of asthma (10 [45%] of 
22) and less likely to be diagnosed with otitis media (1 [5%] of 
22) than those who presented to an OPD (asthma, 3 [9%] of 32, 
P = .002; otitis media, 9 [28%] of 32, P = .028).
A previous diagnosis of asthma was present in 437 (41.4%) 
of 1055 of the study children. Cough was a presenting symp-
tom in 389 (89%) of 437 of those with an underlying diagnosis 
of asthma and in 512 (83%) of 618 of those without an under-
lying diagnosis of asthma (P =  .005). Children with a preex-
isting diagnosis of asthma were significantly more likely to 
have a discharge diagnosis of asthma (200 [45.8%] of 437) but 
not more likely to have a discharge diagnosis of pneumonia 
(26 [5.9%] of 437) than those without a preexisting diagnosis 
of asthma (asthma, 11 [1.8%] of 618, P < .001; pneumonia, 26 
[4.2%] of 618, P = .198). The difference in detection of HMPV 
during ARI in children with a preexisting diagnosis of asthma 
(25 [5.7%] of 437) compared to those without this preexisting 
diagnosis (29 [4.7%] of 618)  was not statistically significant 
(P = .455).
Cough was present more frequently in children with 
HMPV infection (53 [98%] of 54) than in those with HMPV-
negative ARI (848 [85%] of 1001; P = .006). Otherwise, there 
were no significant differences in the clinical features of 
HMPV infections compared to those of infections in which 
HMPV was not detected (Table  1). In addition, we found 
no difference between the proportions of high-risk preex-
isting conditions in the HMPV-positive group and those 
in the HMPV-negative group. However, children with an 
infection in which HMPV was detected were significantly 
more likely to be assigned a discharge diagnosis code of 
pneumonia, other ARI, or bronchiolitis than children with 
HMPV-negative infection and were less likely to be assigned 
a discharge diagnosis code of pharyngitis. Of all 1055 study 
children, 29 (2.7%) were hospitalized and 4 (0.4%) required 
supplemental oxygen. None of the hospitalized older children 
had HMPV, and none of the 4 children who required oxygen 
had HMPV infection.
DISCUSSION
Here, we report that HMPV was detected in 5% of children aged 
5 to 13 who presented to an outpatient or ED setting with ARI; 
those with HMPV-positive ARI had clinical features similar to 
those with ARI for which HMPV was not detected. The only 
clinical feature of HMPV infection observed in our cohort that 
differed significantly from those with HMPV-negative ARI was 
cough, which was present almost universally (53 [98%] of 54) in 
children with HMPV infection. This result suggests that HMPV 
ARI is associated with a higher proportion of lower respiratory 
tract disease than HMPV-negative ARI, particularly given that 
HMPV infection was also associated with an incidence of coded 
pneumonia or bronchiolitis diagnosis that was higher than that 
in the HMPV-negative group. A preexisting asthma diagnosis 
was associated with a discharge diagnosis of asthma, although 
it was not significantly associated with detection of HMPV or a 
discharge diagnosis of pneumonia.
The clinical features of infection we observed in older chil-
dren with HMPV infection were similar to characteristics 
previously reported for HMPV-infected children <5 years old 
enrolled in the NVSN [1]. In the study of younger children 
with ARI, HMPV was detected in 7% of children evaluated in 
an outpatient clinic or ED and in 6% of hospitalized children. 
Hospitalized patients with HMPV-positive ARI were signifi-
cantly older than HMPV-negative patients and were more likely 
to have a high-risk preexisting condition. However, no signif-
icant association with preexisting conditions was observed in 
the outpatient/ED setting in the younger children or in our cur-
rent cohort of older children.
Although HMPV infection was common in this older 
cohort with ARI, no HMPV-positive children aged 5 to 13 years 
were hospitalized. Rates of HMPV-associated hospitalization 
are highest among children <6  months old, but the rates of 
HMPV-associated outpatient visits among children aged 6 to 
59 months remain similar to the rates among young infants [1]. 
This pattern is in contrast to that observed for RSV and coro-
navirus infection, for which rates of symptomatic illness and 
hospitalization decrease markedly after 1 year of age [10, 11]. 
Thus, our findings support the assertion that HMPV, similar 
to influenza [12], causes clinically significant disease not only 
during early childhood but also throughout later childhood. 
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This observation is further supported by findings from another 
multicenter prospective population-based study of hospitalized 
children with pneumonia in which the incidence of HMPV-
associated pneumonia was highest among children <5 years old 
but also remained prevalent in 5- to 9- and 10- to 17-year-old 
children [7].
In a retrospective cohort study at a US children’s hospital, 
90 (11.0%) of 815 hospitalized children with HMPV infection 
were aged 5 to 17 years [13]. The authors estimated that HMPV 
results in approximately 27 000 hospitalizations annually in 
children aged <18  years (mean estimated cost, $277 million 
(95% confidence interval, $246–$308 million). An additional 
1060 HMPV infections occurred that were associated with out-
patient visits, ED visits, or brief (<24-hour) hospitalizations. 
Although those 1060 episodes associated with outpatient visits, 
ED visits, and brief hospitalizations were not stratified accord-
ing to age, the prevalence of HMPV detection among outpa-
tients in our study suggests that children aged >5 years might 
contribute substantially to this burden.
Our study has several limitations. First, the study popula-
tion might not be representative of the entire US population 
or that of other locations, despite the large number of patients 
enrolled at our 3 study sites. Second, children were enrolled 
only between November and May. Thus, our estimate might not 
represent the overall outpatient/ED burden of HMPV infection 
in older children, given that HMPV infection has been associ-
ated with biannual periodicity in some studies, and its season-
ality might extend beyond May [13]. We enrolled children in 
outpatient and ED settings but not inpatients, although patients 
seen in outpatient and ED settings who were admitted were 
included. Thus, detailed features of more complicated or severe 
HMPV infections in older children who were directly admitted 
to the hospital were not captured in our study. Moreover, the 
numbers enrolled did not allow us to calculate rates of HMPV-
associated hospitalization among older children. Our analysis 
did not examine the clinical features of infections with viruses 
other than HMPV, so direct comparisons of the features of 
HMPV infection with those of other viruses in older children 
cannot be made.
In conclusion, HMPV is detected in approximately 1 in 20 
older children with ARI who present to an outpatient or ED 
setting for medical attention. Although outpatient HMPV ARI 
is less severe and costly than ARI that requires hospitaliza-
tion, the number of outpatient ARIs associated with HMPV in 
older children likely represents a substantial health care burden 
among all children.
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